Leading Fill Finish CDMO Service Biologics Industry
.png)
Published: November 2025
Fill / finish is the final step in downstream processing of a product, wherein the purified formulation of the biopharmaceutical is mixed with the necessary excipients and stabilizers. The product is then formulated and aliquoted into the appropriate dosage forms for clinical use or commercial distribution. These operations are automated and are usually carried out under aseptic conditions. Unit operations involved in the fill / finish process include compounding and mixing, filling, lyophilization, closing, sealing, sorting, inspection, labelling and packaging of the product
It is worth highlighting that fill / finish operations are one of the most commonly outsourced operations in the biopharmaceutical industry occupying about one-third of the total market. Drug developers prefer to outsource their fill / finish operations for several reasons. For instance, small biotech companies enter into agreements with fill / finish service providers due to lack of in-house capacity. For companies with in-house fill / finish capabilities, the outsourcing strategy is more complex and depends on a number of factors, such as phase of product development, product life cycle, production volumes and profitability. However, one of the major drivers for outsourcing fill / finish operations of biologics is to gain additional capacity or capability and reduce the risk profile by sharing the overall cost of development
Roots Analysis has conducted an exhaustive study on Biologics Fill Finish Manufacturing Market featuring the current market landscape and future opportunity for the companies engaged in healthcare, over a span of next 10 years.
Top Five Leading Fill Finish CDMO Service Biologics Industry Players
- Lifecore Biomedical
- Lonza
- Novocol Pharma
- Patheon pharma services
- WACKER
Interested in exploring all ~255 players offering biologic fill finish manufacturing related services, along with their recent initiatives?
Discover Below the Details on Leading Fill Finish CDMO Service Biologics Industry Players
Let us dive deep into the details of the top 5 leading fill finish CDMO service biologics industry players. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
1. Lifecore Biomedical
Company Overview
Lifecore Biomedical is a contract development and manufacturing organization which has a broad range of technical capabilities to offer manufacturing services for sterile injectables and high-quality sodium hyaluronate. The firm offers extensive services from process development to cGMP compliant manufacturing, and analytical testing for different types of molecules, such as monoclonal antibodies, proteins, synthetic peptides and small molecules. The company’s well-equipped state-of-the-art facilities have the capability to provide sterilization, filling, assembly, labelling, and packaging services for various sterile, non-sterile formulations and highly viscous substances. Additionally, it is worth highlighting that currently the firm offers contract manufacturing services for around 15 projects (drugs / devices) that are in early stages of development and approximately 10 projects (drugs / devices) that are presently in the later stages of the product lifecycle
List of Biologics Fill Finish Services Offered
The section provides information on the various biologics fill finish services offered by Lifecore Biomedical.
| Parameters |
Deacription |
| Location of Fill / Finish Facilities |
|
| Scale of Operation |
|
| Type of Biologic Manufactured |
|
| Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability |
|
| Type of Dosage Form |
|
| Type of Primary Packaging Container Used |
|
| Biologics Fill / Finish-related Services Offered |
|
| Storage Temperature |
|
Recent Developments
In October 2025, Lifecore Biomedical entered into a strategic agreement with a pharmaceutical company for the commercial manufacturing of injectable pharmaceutical product and becoming the commercial supplier of choice.
To know more about the recent initiatives of Lifecore Biomedical and other fill finish CDMO service biologics industry players, access full report.
2. Lonza
Company Overview
Lonza is a leading drug manufacturing company that is engaged in offering integrated solutions for R&D and manufacturing of biologics to various industry, as well as non-industry stakeholders in the pharmaceutical, healthcare and life sciences domain. It is worth mentioning that the firm operates through four business segments, namely Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Within the Biologics division, the company offers a broad range of services including drug substance development and drug product supply services, in order to cater to the contract development and manufacturing needs of its clients. Additionally, the company extends its services to manufacturers of consumer health products, distributors, formulators and other service-based companies. It is worth noting that the company maintains a global presence with operations spanning across 30 sites, worldwide
List of Biologics Fill Finish Services Offered
The section provides information on the various biologics fill finish services offered by Lonza.
| Parameters | Deacription |
| Location of Fill / Finish Facilities |
|
| Scale of Operation |
|
| Type of Biologic Manufactured |
|
| Cytostatic or Cytotoxic of Highly Potent Substance Filling Capability |
|
| Type of Dosage Form |
|
| Type of Primary Packaging Container Used |
|
| Biologics Fill / Finish-related Services Offered |
|
| Storage Temperature |
|
Recent Developments
In October 2025, Lonza received the Swissmedic approval for its highly potent biologics drug product filling line in Stein.
To know more about the recent initiatives of Lonza and other fill finish CDMO service biologics industry players, access full report.
3. Novocol Pharma
Company Overview
Novocol Pharma is Canadian contract development and manufacturing organization that partners with global pharmaceutical and biopharmaceutical drug developers to offer contract services to support the early development and manufacturing of sterile injectable products. With more than 40 years of experience in the contract manufacturing industry, the firm operates a 200,000 square ft. manufacturing facility located in Ontario, Canada. It is worth highlighting that the facility is well-equipped to provide high-quality drug development, drug product fill / finish, combination drug product assembly, analytical testing and drug delivery design services.
Additionally, an ISO 5 grade A aseptic filling line and an ISO 7 grade C terminally sterilized filling line is also installed in its facility which can accommodate fill volumes ranging from 0.5mL to 10 mL for cartridges, 1 mL to 2.25 mL for prefilled syringes and 2R to 50R vials. Further, the filling lines are designed to handle highly potent substances with an occupational exposure band (OEB) of 0.01µg / m3.
List of Biologics Fill Finish Services Offered
The section provides information on the various biologics fill finish services offered by Novocol Pharma.
| Parameters | Deacription |
| Location of Fill / Finish Facilities |
|
| Scale of Operation |
|
| Type of Biologic Manufactured |
|
| Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability |
|
| Type of Dosage Form |
|
| Type of Primary Packaging Container Used |
|
| Biologics Fill / Finish-related Services Offered |
|
| Storage Temperature |
|
Recent Developments
In September 2025, the first delivery of mRNA vaccines (developed by Moderna) occurred wherein the fill finish and new single-use prefilled syringe was completed by Novocol Pharma.
To know more about the recent initiatives of Novocol Pharma and other fill finish CDMO service biologics industry players, access full report.
4. Pantheon pharma services
Company Overview
Patheon pharma services was established as custom pharmaceuticals in 1974 in Fort Erie, Canada and later, in 1993, it was renamed as Patheon pharma services. In August 2017, Thermo Fisher Scientific acquired the firm, adding its complementary CDMO capabilities to the company’s clinical trial services and bioproduction technologies portfolio. Patheon pharma services provides contract development and manufacturing services by offering integrated and customizable solutions for the development of active pharmaceutical ingredients and biologics, along with production solutions for clinical trials as well as commercial manufacturing and logistics services. With an experience of more than 40 years, the company has served over 800 clients through its state-of-the-art facilities located across 60 locations in North America, Europe, Asia, Africa and Australia. Further, it is worth highlighting that in 2023, the firm was awarded as the Best CDMO in The Medicine Marker’s Company of the Year awards
List of Biologics Fill Finish Services Offered
The section provides information on the various biologics fill finish services offered by Patheon pharma services.
| Parameters | Deacription |
| Location of Fill / Finish Facilities |
|
| Scale of Operation |
|
| Type of Biologic Manufactured |
|
| Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability |
|
| Type of Dosage Form |
|
| Type of Primary Packaging Container Used |
|
| Biologics Fill / Finish-related Services Offered |
|
| Storage Temperature |
|
Recent Developments
In July 2025, Thermo Fischer Scientific expanded its strategic agreement with Sanofi in order to acquire latter’s steriles manufacturing site in New Jersey and continue to manufacture the latte’s therapy portfolio.
To know more about the recent initiatives of Pantheon pharma services and other fill finish CDMO service biologics industry players, access full report.
5. WACKER
Company Overview
WACKER is a multinational CDMO that is widely recognized for offering cost-effective and efficient services to the life sciences domain. The firm has the required capabilities to offer product development and manufacturing services for chemical drugs, discovery services for biologics, preclinical testing, process development, GMP manufacturing, cell banking and quality management. Additionally, the company provides sterile fill / finish services for various biologics, such as live biotherapeutic products, mRNA, plasmid DNA, therapeutic proteins and vaccines. It is worth highlighting that, with an experience of over 20 years in this domain, the company’s state-of-the-art facilities accredited with European Medicines Agency (EMA), and USFDA provides sterile filling for biologics across both clinical and commercial scales of operation
List of Biologics Fill Finish Services Offered
The section provides information on the various biologics fill finish services offered by WACKER.
| Parameters | Deacription |
| Location of Fill / Finish Facilities |
|
| Scale of Operation |
|
| Type of Biologic Manufactured |
|
| Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability |
|
| Type of Dosage Form |
|
| Type of Primary Packaging Container Used |
|
| Biologics Fill / Finish-related Services Offered |
|
| Storage Temperature |
|
Recent Developments
In July 2024, WACKER entered into a strategic agreement with CordenPharma for the production and supply of vaccines for potential future pandemics.
To know more about the recent initiatives of WACKER and other fill finish CDMO service biologics industry players, access full report.
What About Other Leading Fill Finish CDMO Service Biologics Industry Players Around the World?
The above article features the leading fill finish CDMO service biologics industry players selected from a pool of around 255 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources:
- https://ir.lifecore.com/news-releases/news-release-details/lifecore-biomedical-selected-new-commercial-manufacturing
- https://www.lonza.com/media-advisories/2025-10-08-14-00
- https://www.indianpharmapost.com/news/moderna-delivers-canadas-first-locally-manufactured-mrna-vaccines-17857
- https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-and-Sanofi-Expand-Strategic-Partnership-to-Enable-Additional-U-S--Drug-Product-Manufacturing/default.aspx
- https://www.biopharminternational.com/view/wacker-and-cordenpharma-consortium-enters-pandemic-readiness